Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 14;14(1):73.
doi: 10.1186/s12245-021-00397-y.

Pediatric tizanidine toxicity reversed with naloxone: a case report

Doaa Bader  1 , Ahmed Adam  2 , Mohamed Shaban  2 , Bader Alyahya  3
Affiliations

Pediatric tizanidine toxicity reversed with naloxone: a case report

Doaa Bader et al. Int J Emerg Med. .

Abstract

Background: Tizanidine, an α-2 adrenoceptor agonist, is widely prescribed for the management of spasticity in adults. Case reports on pediatric tizanidine overdose are limited. Here, we report a case of pediatric tizanidine toxicity that was reversed with naloxone.

Case presentation: A 3-year-old male presented to the emergency department with lethargy, bradycardia, and bradypnea after accidental ingestion of multiple tizanidine tablets. Improvements in the level of consciousness and respiratory and heart rates were observed after two intravenous administrations of naloxone at a dose of 0.05 and 0.1 mg/kg, respectively.

Conclusions: This case report provides further evidence regarding the use of naloxone as a viable antidote for centrally acting α-2 receptor agonists and presents additional epidemiologic data on childhood tizanidine poisoning.

Keywords: Naloxone; Pediatric; Tizanidine; Toxicology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interest.

References

    1. Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother. 2008;9(12):2209–2215. doi: 10.1517/14656566.9.12.2209. - DOI - PubMed
    1. Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T. A review of spasticity treatments: pharmacological and interventional approaches. Crit Rev Phys Rehabil Med. 2013;25(1-2):11–22. doi: 10.1615/CritRevPhysRehabilMed.2013007945. - DOI - PMC - PubMed
    1. Kamen L, Henney HR, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin. 2008;24(2):425–439. doi: 10.1185/030079908X261113. - DOI - PubMed
    1. Lowry JA, Brown JT. Significance of the imidazoline receptors in toxicology. Clin Toxicol (Phila) 2014;52(5):454–469. doi: 10.3109/15563650.2014.898770. - DOI - PubMed
    1. Spiller HA, Bosse GM, Adamson LA. Retrospective review of tizanidine (zanaflex®) overdose. J Toxicol Clin Toxicol. 2004;42(5):593–596. doi: 10.1081/CLT-200026978. - DOI - PubMed

LinkOut - more resources